A ltieri and Edgington 1 have reported recently that a membrane protein similar to the light chain of factor Va might be the membrane receptor of factor Xa on monocytes. This protein, called effector protease receptor-1 (EPR-1), behaves as a cofactor for factor Xa to catalyze prothrombin activation in the absence of added factor Va. 2 Recently, we and others demonstrated the existence of such a population of high-affinity, functional, factor Xa-binding sites in human vascular endothelial cells (HUVECs) and showed that exposure of HUVECs to factor Xa induced phosphoinositide turnover and an increase in intracellular free Ca 2ϩ . 3, 4 Most important, through binding to this receptor, factor Xa was also a potent mitogen for endothelial cells. 3 Moreover, a recent article by Papapetropoulos et al 5 showed increased interleukin-6 release by HUVECs after treatment with factor Xa. These activities of factor Xa are affected by selective factor Xa inhibitors, which suggests that occupancy of EPR-1 alone by factor Xa is not sufficient for cell activation and that protease activity is required for factor Xa to induce signal transduction and subsequent activation of vascular endothelial cells. 6 In this respect, factor Xa behaves like thrombin or trypsin, both of which require full catalytic activity to exhibit cellular effects, 7, 8 but differs from them by the fact that both thrombin and trypsin receptors (respectively, PAR-1 [protease-activated receptor-1] and PAR-2 [protease-activated receptor-2]) need to be specifically cleaved by these proteases to be activated. 9 Here we show that EPR-1 is necessary to localize factor Xa in close proximity to the cellular membrane where it then selectively cleaves and activates PAR-2, thus representing a novel mode of cascade receptor activation.
Methods

Cell Culture and Free [Ca 2؉ ] i Measurements
HUVECs (Clonetics) were routinely cultured in 75-cm 2 flasks coated with human fibronectin (5 g/cm 2 ) in RPMI 1640 medium containing 10% fetal bovine serum, 100 IU penicillin, 100 g/mL streptomycin, 2 mmol/L glutamine, heparin (100 g/mL), and 30 g/mL endothelial cell growth supplement (ECGS, Sigma Chemical Co). HUVECs, used from the third to the sixth passage, were detached with a nonenzymatic cell dissociation solution (Sigma) and resuspended in physiological salt solution (composition in mmol/L: NaCl 145, KCl 5, MgCl 2 1, CaCl 2 10, glucose 5.6, and HEPES/NaOH 5, pH 7.4.) containing fura 2-acetoxymethylester (1 mol/L) and incubated at 37°C for 30 minutes as previously described. 6 For the preincubation experiments, HUVECs were incubated for 10 minutes at 37°C with the various proteases at the indicated concentrations. After 2 washes in physiological salt solution, cells were resuspended (3ϫ10 4 cells/mL), and the experiments were performed at 37°C under constant stirring in a spectrofluorometer.
Binding Experiments
125
I-labeled factor Xa binding experiments were performed on cell monolayers cultured in 24-well cluster plates (3ϫ10 5 cells/well) as previously described. 3, 6 Medium was aspirated, and the cells were washed twice with buffer containing (in mmol/L) NaCl 137, KCl 4, glucose 11, EDTA 10, and HEPES 10, pH 7.45. Cells were then incubated at 4°C with 200 L of the same buffer without EDTA containing 0.5% bovine serum albumin and 5 mmol/L CaCl 2 in the presence of human 125 I-factor Xa (1 nmol/L; 2000 Ci/mmol, Amersham) and the tested compounds. After 120 minutes, the buffer was aspirated and the cells washed 3 times with ice-cold binding buffer. Cells were then digested with 1 mL of 0.2N NaOH, 1% SDS, and 10 mmol/L EDTA for 5 minutes, and the resulting solution was counted in a gamma counter. Results for equilibrium binding experiments were analyzed as described. 10 
Hydrolysis of PAR Peptides
The PAR-1 peptide (biotinyl-LDPRSFLLRNPNDKYEPFWED-EEE-Edans), PAR-2 peptide (biotinylaminocaproyl-RSSKGRSLIGKVDGTSHVTGKE-Edans), or mutated PAR-2 peptide (biotinylaminocaproyl-RSSKGASLIGKVDGTSHVTGKEEdans; Neosystem) was solubilized at a final concentration of 10 mol/L in HEPES buffer containing (in mmol/L) NaCl 137, KCl 4, glucose 11, and CaCl 2 5,pH 7.45, and incubated for 30 minutes at 37°C in the presence of 100 nmol/L factor Xa, trypsin, or thrombin. The reaction was stopped by the addition of 10 mol/L DX9065 (Daiichi Pharmaceuticals), 100 g/mL soybean trypsin inhibitor (SBTI), or 200 nmol/L hirudin (SanofiϳSynthélabo), respectively. The solution was then incubated for 30 minutes at 37°C under constant stirring in the presence of streptavidin-coated beads (Sigma). The samples were centrifuged, and the optical density at 360 nm was measured on the supernatants.
To determine the level of hydrolysis of the PAR peptides by HUVEC-bound factor Xa, confluent HUVECs (3ϫ10 5 cells/well) cultured in 24-well cluster plates were rinsed and preincubated for 120 minutes at 4°C with factor Xa (10 nmol/L) diluted in buffer (HEPES buffer containing 137 mmol/L NaCl, 4 mmol/L KCl, 11 mmol/L glucose, and 5 mmol/L CaCl 2 , pH 7.45) in the absence or presence of the anti-EPR-1 monoclonal antibody B6 (100 g/mL; a kind gift of Dr D. Altieri, Yale University, New Haven Conn), L 83 -L 88 -G (10 mol/L), or DX9065 (1 mol/L). Unbound factor Xa was removed by washing 6 times with binding buffer, and the cells were incubated for 30 minutes at 37°C with 10 nmol/L 125 I-PAR-1 and 125 I-PAR-2 peptides (Amersham). The reaction was stopped by adding 10 mol/L DX9065, and 100 L of the supernatant was incubated for 30 minutes under constant stirring in the presence of streptavidin-coated beads. The samples were centrifuged and rinsed, and the radioactivity was measured by scintillation counting. The same experiments without factor Xa were performed as controls.
Phosphoinositide Turnover in Transfected HEK293 Cells
Human embryonic kidney (HEK) 293 cells expressing PAR-1 and PAR-2 were generated by transfecting wild-type HEK293 cells by calcium phosphate precipitation and collecting the cells 72 hours later for transient expression. Expression vectors for PAR-1 and PAR-2 were kind gifts of Dr J.C. Chambard (URM 6543, CNRS, Nice, France). Phosphoinositide turnover was measured on confluent cell monolayers as described by Berridge et al. 11 In brief, cells were incubated for 72 hours in normal-culture medium containing myo- 
Immunohistochemical Detection of Cleaved PAR-1 and PAR-2 on HUVECs
PAR-1 and PAR-2 immunohistochemistry was performed on cultured HUVECs that were fixed with 4% formaldehyde. Cell monolayers were reacted with an anti-PAR-1 monoclonal antibody recognizing the N-terminal peptide 35-46 of the receptor (Immunotech) or with an anti-PAR-2 monoclonal antibody recognizing the N-terminal peptide 23-32 of the receptor (a kind gift of Dr D. Altieri, Yale University, New Haven, Conn). The cells were then incubated for 30 minutes at 4°C with a biotinylated secondary anti-IgG monoclonal antibody (Sigma) in blocking buffer. Cells were rinsed and incubated with avidin-horseradish peroxidase complex (Vector Laboratories) for 30 minutes and developed for 10 minutes with a fluorescein-tyramine complex (NEN Life Science). The stained cells were mounted by using the ProLong Antifade kit (Molecular Probes). For quantification of the cleaved PARs, a similar method was used, except that a 125 I-anti-IgG monoclonal antibody (Amersham) was used to detect the presence of the primary antibodies. Triplicate incubations were performed and terminated by the addition of 3 mL of ice-cold assay buffer. Cells were then rinsed and incubated for 30 minutes in 0.2 mL of 0.5N NaOH, 1% SDS, and 10 mmol/L EDTA, followed by rapid vacuum filtration over glassfiber filters (Skatron Instruments Inc). Filters were then washed twice with 5 mL of ice-cold incubation buffer and dried, and the radioactivity was measured by scintillation counting. Nonspecific binding was defined as the binding of the 125 I-anti-IgG antibody measured in the absence of the primary antibody, and specific binding was defined as the difference between total binding and nonspecific binding.
Results and Discussion
To determine whether factor Xa could activate HUVECs in such a PAR-dependent, EPR1-mediated manner, we measured the effect of factor Xa on intracellular Ca 2ϩ increase in HUVECs. This parameter has been previously found to be highly sensitive not only to this protease but also to others, such as thrombin, trypsin, SFLLRN, and SLIGKV, the latter 2 peptides that activate PAR-1 and PAR-2, respectively, on vascular endothelial cells. 9 These agonists induced an intracellular Ca 2ϩ increase in HUVECs in a dose-dependent manner ( Figure IA ). In this cell system, in which EPR-1 was detected by Western blotting (not shown), factor Xa induced an intracellular Ca 2ϩ increase in an EPR-1-dependent manner, as demonstrated by the inhibitory effect of B6, a monoclonal anti-EPR-1 antibody that has been described several times as an inhibitor of binding of factor Xa to vascular endothelial and smooth muscle cells, 1, 5, 6 or with Leu 83 -Leu 88 -G, a peptide representing the interconnecting EGF sequence in factor Xa, both of which blocked the binding of factor Xa to EPR-1 on HUVECs and inhibited its effect on intracellular Ca 2ϩ (Figures IB and IC and Table I ). Comparative dose-response curves for L 83 -L 88 -G and B6 demonstrated a good correlation between their effect on the binding of 125 I-factor Xa to HUVECs and their effect on the calcium response evoked by factor Xa on these cells ( Figure  IC) . It is noteworthy that at maximal factor Xa binding-inhibitory concentrations (10 mol/L and 100 g/mL, respectively), neither L 83 -L 88 -G nor B6 affected the catalytic activity of factor Xa (not shown). Moreover, a nonrelevant monoclonal antibody (anti-ELAM-1), as well as a "scrambled" peptide of the Leu 83 -Leu 88 -G sequence, hardly affected the effect of factor Xa on intracellular calcium (not shown).
The first evidence of an original mode of receptor activation by factor Xa came from the observation of an inhibitory effect of DX9065, a direct inhibitor of factor Xa 12 that strongly affected the factor Xa-induced intracellular Ca 2ϩ increase, with an IC 50 of 0.23 mol/L, but did not interfere with the binding of factor Xa to EPR-1 ( Figure IB and Table   I ). This effect of factor Xa was not affected by high doses of aprotinin or hirudin, which shows that it was not due to thrombin or trypsin generation that might have occurred at the cell surface (Table I ). In this cell system, we also found that preincubation of the cells with pertussis toxin (50 ng/mL) strongly affected (86% inhibition, PϽ0.001) 100 nmol/L factor Xa-induced intracellular Ca 2ϩ increase (not shown), indicating that factor Xa not only binds to EPR-1 (which is not coupled to G proteins) but also interacts with and activates a specific G protein-coupled receptor. This represents further evidence for an interaction with a PAR receptor, shown to be coupled to G proteins. 9 To gain further insight into the nature of this receptor (ie, whether it is thrombin-or trypsin-sensitive), we performed desensitization experiments. As shown in Figure II , when HUVECs were first challenged with thrombin or with the PAR-1 agonist SFLLRN, a second challenge with these compounds was ineffective, thus showing complete desensitization of the PAR-1 receptor. Under these conditions, factor Xa, the PAR-2 agonist peptide SLIGKV, or trypsin still elicited a marked intracellular Ca 2ϩ increase ( Figure II and Table II ) on these thrombindesensitized cells, therefore showing that factor Xa does not activate HUVECs by means of selective activation of PAR-1. The same results were found with TFLLRNPNDK, a peptide that has been recently shown to activate PAR-1 selectively with no effect on PAR-2 13 ( Figure II) . On the contrary, on HUVEC in which the calcium response to trypsin or SLIGKV was desensitized, the response to factor Xa was abolished (Figure II and Table II) , therefore showing that desensitization of HUVECs for the PAR-2 response hinders factor Xa activation of the cells. Under these conditions, preincubation of the cells with trypsin (100 nmol/L, 10 minutes, 37°C) did not affect the binding of 125 I-factor Xa to HUVECs, thus showing that desensitization of the factor Xa response did not occur as a result of nonspecific digestion of EPR-1 but rather at the level of PAR-2 that was desensitized in HUVECs after incubation with trypsin. 14 This observation of an effect of factor Xa on PAR-2 was further confirmed on cells preincubated with factor Xa that, in this case, were desensitized not only for factor Xa itself ( Figure II) but also for the selective PAR-2 activator, SLIGKV, whereas selective PAR-1 activation was unaffected ( Figure II) . Under these latter experimental conditions, the effect of trypsin was not totally reduced (50% inhibition, PϽ0.05), an effect that could have been due to a nonspecific effect of this protease on PAR-1 9,14 but that could also be explained by a possible "recycling" of PAR-2 at the cell surface during the experiment performed at 37°C, thus allowing partial resensitization of the cells to this protease. In an attempt to further clarify this point, we performed the same experiments in the presence of brefeldin A, a compound that has been shown, by disrupting Golgi stores of PAR-2, to strongly attenuate resensitization of the calcium response of HUVECs to trypsin. 15 Under these conditions (incubation with 10 g/mL brefeldin A), we found that low concentrations of trypsin (10 nmol/L) totally desensitized the cells for additional stimulation with trypsin or factor Xa (10 nmol/L) but were without effect on the activity of thrombin (10 nmol/L), thus confirming our earlier observation of an effect of factor Xa via PAR-2 only. At this stage, although we have shown that factor Xa acted in an EPR-1-dependent manner via selective activation of PAR-2, we prepared to demonstrate that this protease cleaved PAR-2 in vitro and on the cells. For this purpose, we incubated factor Xa in the presence of synthetic peptides representing the N-terminal extracellular domains of PAR-1 and PAR-2, cleaved after incubation of the cells with thrombin and trypsin, respectively. As shown in Figure IIIA , factor Xa, either alone or in the presence of calcium or factor Va, did not hydrolyze the synthetic 23-mer peptide corresponding to the sequence present in PAR-1. This peptide was optimally cleaved by thrombin (33% hydrolysis) and slightly hydrolyzed by trypsin (8% hydrolysis). On the contrary, trypsin and factor Xa cleaved the synthetic 22-mer PAR-2 peptide (Figure IIIB) at a site that corresponded to the expected cleavage site of trypsin and tryptase (Arg-9; not shown). This peptide was not cleaved by thrombin (3% hydrolysis). Proteolytic cleavage of the N-terminal extracellular domain of the PAR-2 receptor by factor Xa was highly selective, as shown by the lack of efficacy of this protease for a "mutated" PAR-2 peptide, in which Arg-9 was replaced by Ala-9 ( Figure IIIC) . It is noticeable that cleavage of the PAR-2 peptide by factor Xa occurred only in the presence of calcium but independently of factor Va, thus explaining why other authors 16 who performed similar experiments, but without calcium, did not find any cleavage of PAR-2 by factor Xa.
Similarly, the radiolabeled PAR-1 peptide was not cleaved by factor Xa preincubated with HUVECs under conditions where increased prothrombin activation by factor Xa bound to EPR-1 was already demonstrated, 6 whereas under the same experimental conditions, the radiolabeled PAR-2 peptide was almost totally hydrolyzed by HUVEC-bound factor Xa (Figure IIIE) . This hydrolysis by factor Xa was strongly reduced in the presence of DX9065 or after preincubation of the cells with the L 83 -L 88 -G peptide or B6, 2 compounds that have been shown to inhibit the binding of factor Xa to EPR-1 on HUVECs 3 ( Figure IB) . When a higher concentration of DX9065 (10 mol/L) was used, total inhibition of the activity of HUVEC-bound factor Xa was observed (98% inhibition, PϽ0.001). It is notable that hydrolysis of the PAR-2 peptide by HUVEC-bound factor Xa occurred at much lower enzyme and substrate concentrations than those used in the purified systems, which suggests that EPR-1 acts as a cofactor for factor Xa to cleave PAR-2. In this respect, the role of EPR-1 might be very similar to that reported for factor V/Va that, in the presence of anionic phospholipids and calcium, strongly enhances thrombin generation by factor Xa. 3 The requirement of PAR-2 for factor Xa to activate the cells was further demonstrated in HEK293 cells (which constitutively express EPR-1, as assessed by Western blotting; not shown). Factor Xa could only increase the production of inositol monophosphate when PAR-2 was present and showed no effect on wild-type cells or when PAR-1 was transfected ( Figure IV) .
To further prove that factor Xa cleaves PAR-2 at the surface of HUVECs and "unmasks" a new amino terminus that then serves as a tethered peptide ligand, we have an antibody directed against the 40-mer peptide cleaved by proteases on PAR-2. This antibody allowed us to selectively detect, both qualitatively and quantitatively, the presence of PAR-2 in the nonactivated state (ie, not cleaved by proteases) at the surface of the cells. As shown in Figure V , after incubation of HUVECs with factor Xa or trypsin (Figures c and Vd), the amount of uncleaved PAR-2 detected by the antibody strongly decreased (98% and 95% decrease, respectively; PϽ0.001). Incubation of the cells with thrombin, however, only slightly decreased the amount of uncleaved PAR-2 ( Figure Vb) . On the contrary, immunodetection of uncleaved PAR-1 by a similar method (Figures VIIe through Vg) confirmed that PAR-1 was highly activated after incubation with thrombin (93% decrease, PϽ0.001), whereas it was not affected by factor Xa ( Figure Vg) .
In conclusion, we now report that factor Xa, in cooperation with its receptor on endothelial cells, EPR-1, cleaves PAR-2 by a novel mode of cascade receptor activation. 
